Stockscreener 앱 받기
188.69
1.08%
2.02
시장 영업 전:
188.70
0.010
+0.01%
전일 마감가:
$186.67
열려 있는:
$186.93
하루 거래량:
895.67K
Relative Volume:
0.87
시가총액:
$11.62B
수익:
$4.27B
순이익/손실:
$-356.15M
주가수익비율:
-31.61
EPS:
-5.9702
순현금흐름:
$1.19B
1주 성능:
-4.14%
1개월 성능:
+13.86%
6개월 성능:
+47.39%
1년 성능:
+35.80%
1일 변동 폭
$184.15
$190.67
1주일 범위
$184.15
$198.00
52주 변동 폭
$95.49
$198.00
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
188.69 | 11.49B | 4.27B | -356.15M | 1.19B | -5.9702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-15 | 개시 | Deutsche Bank | Buy |
| 2025-03-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Buy |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
GW&K Investment Management LLC Sells 17,849 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Mixed Recent Returns And A 5.7% Undervaluation Estimate - simplywall.st
Insider Sell: Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus
JAZZ SEC FilingsJazz Pharmaceuticals Plc 10-K, 10-Q, 8-K Forms - Stock Titan
https://www.msn.com/en-us/money/companies/jazz-pharmaceuticals-plc-jazz-reports-1-2-billion-q4-revenue-beats-1-17b-estimate/ar-AA1Xsvc3?ocid=finance-verthp-feeds - MSN
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate - Yahoo! Finance Canada
Jazz Pharmaceuticals (NASDAQ: JAZZ) lists option-derived shares for sale via Merrill Lynch - Stock Titan
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After A 36% One Year Share Price Jump - simplywall.st
JAZZ: Record growth, pipeline advances, and rare disease focus drive strong 2026 outlook - TradingView
JAZZ: Record growth, pipeline advances, and new filings drive strong outlook for 2026 - TradingView
JAZZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 3,415 Shares - MarketBeat
Jazz Pharmaceuticals Director Sells 3,415 Shares - TradingView
Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Neena Patil Sells 55,600 Shares - MarketBeat
Jazz Pharmaceuticals (JAZZ) director sells 3,415 shares after option exercise - Stock Titan
Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Patricia Carr Sells 1,117 Shares - MarketBeat
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) SVP Sells 5,343 Shares of Stock - MarketBeat
Patricia Carr Sells 1,253 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock - MarketBeat
Jazz Pharmaceuticals (JAZZ) CFO granted 11,857 restricted stock units - Stock Titan
Jazz Pharmaceuticals (JAZZ) EVP awarded 9,782 restricted stock units in Form 4 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) grants 14,822 RSUs to R&D leader - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP reports share award and open-market sales - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO receives 44,465 restricted stock units - Stock Titan
Jazz Pharmaceuticals (JAZZ) director receives 1,527-share restricted stock unit grant - Stock Titan
Jazz Pharmaceuticals Insider Sold Shares Worth $1,039,134, According to a Recent SEC Filing - marketscreener.com
Jazz Pharmaceuticals (NASDAQ: JAZZ) EVP Patil sells 55,600 shares - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP reports RSU grant and tax-driven share sale - Stock Titan
Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth - Sleep Review
Jazz Pharmaceuticals (JAZZ) Stock Analysis: Unveiling A 17% Upside Potential For Investors - DirectorsTalk Interviews
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now? - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Is Up 10.4% After Record Q4 Revenue And New Oncology Data Release - simplywall.st
JAZZ Should I Buy - Intellectia AI
Patricia Carr reports JAZZ (NASDAQ: JAZZ) sales of 1,253 and 4,660 shares - Stock Titan
[144] Jazz Pharmaceuticals plc SEC Filing - Stock Titan
This Jazz Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Benzinga
JAZZ Receives New Overweight Rating as Barclays Initiates Coverage | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Stock Surges 13% on Oncology Breakthrough: Here’s Where the Stock Could Go in 2026 - TIKR.com
Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock? - TradingView
Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Overweight Rating from Analysts at Barclays - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Quarterly Profit Of US$203 Million Tests Trailing Loss Narrative - simplywall.st
Jazz Pharmaceuticals (NASDAQ: JAZZ) Form 144: 10,116 restricted shares; insider sold 2,238 - Stock Titan
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise’s Outlook (NASDAQ:JAZZ) - Seeking Alpha
Fox Run Management L.L.C. Invests $1.37 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Citigroup Inc. - MarketBeat
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Quarter And 2026 Guidance - Yahoo Finance
Jazz Pharmaceuticals stock hits 52-week high at $183.10 By Investing.com - Investing.com Australia
No-Moat Jazz's Growth Driven by Newly Launched Assets and Pending Expansion of Ziihera - Morningstar
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):